Comparison of baseline main characteristics and PRO and geriatric measures between recipients of less-intensive vs intensive regimens within the prospective cohort with AML-CM score ≥4
| . | Less intensive . | Intensive . | P . |
|---|---|---|---|
| Baseline main characteristics | |||
| Age ≥65 y | 80 | 33 | <.0001 |
| Age ≥75 y | 32 | 3 | <.0001 |
| Augmented HCT-CI score ≥4 | 64 | 54 | .04 |
| Mean augmented HCT-CI score | 5.0 | 4.2 | .006 |
| 2017 ELN adverse risk group | 53 | 31 | <.0001 |
| AML-CM score ≥7 | 73 | 50 | <.0001 |
| Mean AML-CM score | 8.7 | 6.8 | <.0001 |
| Cumulative incidence of achieving CR | 44 | 82 | <.0001 |
| PRO and geriatric measures | |||
| Fried frailty index score >0 (prefrail + frail) | 56 | 66 | .16 |
| Fried frailty index score 3-5 (frail) | 0 | 3 | .18 |
| BOMC ≥6 (moderate/severe impairment)* | 31 | 23 | .17 |
| Geriatric (other, yes/no)* | 32 | 36 | .58 |
| Geriatric (falls, yes/no)* | 18 | 12 | .25 |
| Walk test >0.8 m/s | 45 | 48 | .58 |
| PHQ-9 depression ≥10 (depressed) | 36 | 33 | .67 |
| PHQ-9 major depressive disorder (without functional impairment) | 16 | 17 | .80 |
| PHQ-9 major depressive disorder (with functional impairment) | 8 | 7 | .69 |
| ADL <14 (dependent) | 38 | 24 | .01 |
| IADL <14 (dependent) | 63 | 53 | .10 |
| BOMC | 4.1 (4.4) | 3.2 (3.9) | .17 |
| Geriatric (vision)* | 2.0 (0.8) | 1.9 (0.7) | .22 |
| Geriatric (hearing)* | 2.0 (0.9) | 1.9 (0.8) | .40 |
| KPS | 74 (16) | 80 (11) | <.0001 |
| Walk test mean time | 6.0 (4.0) | 5.8 (3.5) | .74 |
| FACT-PWB (average) | 2.8 (1.0) | 2.7 (0.9) | .55 |
| FACT-SWB (average) | 3.5 (0.6) | 3.4 (0.7) | .34 |
| FACT-EWB (average) | 2.8 (0.8) | 2.9 (0.8) | .52 |
| FACT-FWB (average) | 2.3 (1.0) | 2.1 (0.9) | .06 |
| FACT-G | 72 (18) | 71 (15) | .82 |
| EQ5D-Index | 0.78 ((0.19) | 0.78 (0.19) | .80 |
| SAL score | 2.0 (1.0) | 2.0 (1.0) | .88 |
| Social support | 30 (4.9) | 30 (4.8) | .90 |
| PHQ-9 depression | 7.6 (5.5) | 7.7 (5.6) | .95 |
| . | Less intensive . | Intensive . | P . |
|---|---|---|---|
| Baseline main characteristics | |||
| Age ≥65 y | 80 | 33 | <.0001 |
| Age ≥75 y | 32 | 3 | <.0001 |
| Augmented HCT-CI score ≥4 | 64 | 54 | .04 |
| Mean augmented HCT-CI score | 5.0 | 4.2 | .006 |
| 2017 ELN adverse risk group | 53 | 31 | <.0001 |
| AML-CM score ≥7 | 73 | 50 | <.0001 |
| Mean AML-CM score | 8.7 | 6.8 | <.0001 |
| Cumulative incidence of achieving CR | 44 | 82 | <.0001 |
| PRO and geriatric measures | |||
| Fried frailty index score >0 (prefrail + frail) | 56 | 66 | .16 |
| Fried frailty index score 3-5 (frail) | 0 | 3 | .18 |
| BOMC ≥6 (moderate/severe impairment)* | 31 | 23 | .17 |
| Geriatric (other, yes/no)* | 32 | 36 | .58 |
| Geriatric (falls, yes/no)* | 18 | 12 | .25 |
| Walk test >0.8 m/s | 45 | 48 | .58 |
| PHQ-9 depression ≥10 (depressed) | 36 | 33 | .67 |
| PHQ-9 major depressive disorder (without functional impairment) | 16 | 17 | .80 |
| PHQ-9 major depressive disorder (with functional impairment) | 8 | 7 | .69 |
| ADL <14 (dependent) | 38 | 24 | .01 |
| IADL <14 (dependent) | 63 | 53 | .10 |
| BOMC | 4.1 (4.4) | 3.2 (3.9) | .17 |
| Geriatric (vision)* | 2.0 (0.8) | 1.9 (0.7) | .22 |
| Geriatric (hearing)* | 2.0 (0.9) | 1.9 (0.8) | .40 |
| KPS | 74 (16) | 80 (11) | <.0001 |
| Walk test mean time | 6.0 (4.0) | 5.8 (3.5) | .74 |
| FACT-PWB (average) | 2.8 (1.0) | 2.7 (0.9) | .55 |
| FACT-SWB (average) | 3.5 (0.6) | 3.4 (0.7) | .34 |
| FACT-EWB (average) | 2.8 (0.8) | 2.9 (0.8) | .52 |
| FACT-FWB (average) | 2.3 (1.0) | 2.1 (0.9) | .06 |
| FACT-G | 72 (18) | 71 (15) | .82 |
| EQ5D-Index | 0.78 ((0.19) | 0.78 (0.19) | .80 |
| SAL score | 2.0 (1.0) | 2.0 (1.0) | .88 |
| Social support | 30 (4.9) | 30 (4.8) | .90 |
| PHQ-9 depression | 7.6 (5.5) | 7.7 (5.6) | .95 |
Data are given as % or mean (standard deviation).
ADL, activities of daily living; BOMC, Blessed Orientation Memory Concentration; CR, complete remission; EQ5D, EuroQoL 5-dimensional health-related quality of life assessment; FACT-EWB, Functional Assessment of Cancer Therapy–Emotional Well-Being; FACT-FWB, Functional Assessment of Cancer Therapy–Functional Well-Being; FACT-G, Functional Assessment of Cancer Therapy–General; FACT-PWB, Functional Assessment of Cancer Therapy–Physical Well-Being; FACT-SWB, Functional Assessment of Cancer Therapy–Social Well-Being; IADL, instrumental activities of daily living; PHQ-9, Patient Health Questionnaire-9; SAL, Study Alliance Leukemia.
These tests were administered only to patients age ≥60 years per study protocol.